Сŷ��Ƶ

Сŷ��Ƶ and BluMaiden Biosciences Pte. Ltd. (“BluMaiden BioSciences”) Form Strategic Collaboration to Introduce Novel Insights into Clinical Trials

Сŷ��Ƶ Completes $19 Million Second Close of Series C Funding Led by Oppenheimer & Co. Inc. (“Oppenheimer”)

Сŷ��Ƶ Completes $36 Million First Close of Series C Funding Led by Oppenheimer Holdings

Leading Singaporean Diagnostic Center Increases MRI Capacity to Expand Patient Access to Сŷ��Ƶ’s LiverMultiScan

Сŷ��Ƶ and Nuance Collaborate to Scale Access to AI-Enabled Integrated Digital Care Platforms to Improve Patient Care for Metabolic Disease

FDA awards Сŷ��Ƶ major grant for the qualification of its noninvasive diagnostic biomarker to reduce liver biopsy in drug trials

LiverMultiScan shown to be a cost-effective alternative to liver biopsies for monitoring patients with autoimmune hepatitis

FDA Grants Clearance to Сŷ��Ƶ’s CoverScan – A New Platform-Based Tool to Assess Multiple Organs in One MRI Scan

LiverMultiScan® detected earlier stages of treatable disease in patients with autoimmune hepatitis to allow tailored treatment